Cited 9 times in
S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 구자승 | - |
dc.contributor.author | 김민정 | - |
dc.contributor.author | 김승일 | - |
dc.contributor.author | 김은경 | - |
dc.contributor.author | 김주항 | - |
dc.contributor.author | 박병우 | - |
dc.contributor.author | 박세호 | - |
dc.contributor.author | 손주혁 | - |
dc.contributor.author | 이수현 | - |
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2014-12-18T09:50:20Z | - |
dc.date.available | 2014-12-18T09:50:20Z | - |
dc.date.issued | 2013 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/88926 | - |
dc.description.abstract | BACKGROUND: This study evaluated the efficacy and safety of S-1 combined with docetaxel (SD) following doxorubicin plus cyclophosphamide (AC) as neoadjuvant therapy in patients with HER2-negative, stage II-III breast cancer. METHODS: Patients received AC every 3 weeks for four cycles followed by S-1 (30 mg/m2 orally b.i.d. on days 1-14) and docetaxel (75 mg/m2 i.v. on day 1) every 3 weeks for four cycles. The primary endpoint was the pathological complete response (pCR) rate in breast and axillary lymph nodes. RESULTS: The study included 49 patients with a median age of 43 years. The median breast tumor size was 4.0 cm by palpation. All patients were positive for involvement of axillary lymph node and five patients also had supraclavicular lymph node metastasis, which was confirmed by histological examination. In total, 85.4% of patients (41/49) completed eight cycles of therapy and 95.9% of patients (47/49) received curative surgery. The pCR rate was 22.5% (n = 11). The clinical response rate was 67.4%. During SD chemotherapy, the most frequent grade 3-4 toxicity was neutropenia (8.5% by cycle). There was a single treatment-related mortality from severe neutropenia. Grade 3 S-1 specific toxicities such as epigastric pain (12.2% by person), stomatitis (4.1% by person), and diarrhea (2.0% by person) were also observed. In particular, gastrointestinal discomfort led to dose reduction of S-1 in 45.8% of patients. CONCLUSIONS: Given all axillary lymph node positive diseases, neoadjuvant S-1 combined with docetaxel following AC showed a favorable anti-tumor activity but gastrointestinal discomfort should be carefully considered for future studies. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.relation.isPartOf | BMC CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Breast Neoplasms/drug therapy* | - |
dc.subject.MESH | Breast Neoplasms/pathology | - |
dc.subject.MESH | Cyclophosphamide/administration & dosage | - |
dc.subject.MESH | Doxorubicin/administration & dosage | - |
dc.subject.MESH | Drug Combinations | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Induction Chemotherapy/adverse effects | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoadjuvant Therapy/adverse effects | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Oxonic Acid/administration & dosage | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Taxoids/administration & dosage | - |
dc.subject.MESH | Tegafur/administration & dosage | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Tumor Burden | - |
dc.title | S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학) | - |
dc.contributor.googleauthor | Yong Wha Moon | - |
dc.contributor.googleauthor | Soohyeon Lee | - |
dc.contributor.googleauthor | Byeong-Woo Park | - |
dc.contributor.googleauthor | Eun-Kyung Kim | - |
dc.contributor.googleauthor | Seung Il Kim | - |
dc.contributor.googleauthor | Ja Seung Koo | - |
dc.contributor.googleauthor | Seho Park | - |
dc.contributor.googleauthor | Min Jung Kim | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.contributor.googleauthor | Joo-Hang Kim | - |
dc.contributor.googleauthor | Joohyuk Sohn | - |
dc.identifier.doi | 10.1186/1471-2407-13-583 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00198 | - |
dc.contributor.localId | A00658 | - |
dc.contributor.localId | A00801 | - |
dc.contributor.localId | A00945 | - |
dc.contributor.localId | A01475 | - |
dc.contributor.localId | A01524 | - |
dc.contributor.localId | A01995 | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A00473 | - |
dc.contributor.localId | A02898 | - |
dc.relation.journalcode | J00351 | - |
dc.identifier.eissn | 1471-2407 | - |
dc.identifier.pmid | 24314307 | - |
dc.subject.keyword | Breast cancer | - |
dc.subject.keyword | Neoadjuvant chemotherapy | - |
dc.subject.keyword | S-1 | - |
dc.subject.keyword | Docetaxel | - |
dc.subject.keyword | Pathological complete response | - |
dc.contributor.alternativeName | Koo, Ja Seung | - |
dc.contributor.alternativeName | Kim, Min Jung | - |
dc.contributor.alternativeName | Kim, Seung Il | - |
dc.contributor.alternativeName | Kim, Eun Kyung | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.alternativeName | Park, Byeong Woo | - |
dc.contributor.alternativeName | Park, Se Ho | - |
dc.contributor.alternativeName | Sohn, Joo Hyuk | - |
dc.contributor.alternativeName | Lee, Soo Hyeon | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Koo, Ja Seung | - |
dc.contributor.affiliatedAuthor | Kim, Seung Il | - |
dc.contributor.affiliatedAuthor | Kim, Eun-Kyung | - |
dc.contributor.affiliatedAuthor | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | Park, Byeong Woo | - |
dc.contributor.affiliatedAuthor | Park, Se Ho | - |
dc.contributor.affiliatedAuthor | Sohn, Joo Hyuk | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Kim, Min Jung | - |
dc.contributor.affiliatedAuthor | Lee, Soo Hyeon | - |
dc.contributor.affiliatedAuthor | 구자승 | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 13 | - |
dc.citation.startPage | 583 | - |
dc.identifier.bibliographicCitation | BMC CANCER, Vol.13 : 583, 2013 | - |
dc.identifier.rimsid | 33913 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.